|
gptkbp:instanceOf
|
acute myeloid leukemia subtype
|
|
gptkbp:alsoKnownAs
|
gptkb:acute_promyelocytic_leukemia
|
|
gptkbp:class
|
French-American-British (FAB) classification
|
|
gptkbp:complication
|
disseminated intravascular coagulation
|
|
gptkbp:firstDescribed
|
1957
|
|
gptkbp:hasCommonAgeGroup
|
young to middle-aged adults
|
|
gptkbp:hasCommonSymptoms
|
gptkb:anemia
bleeding
fatigue
infections
|
|
gptkbp:hasDiagnosticMethod
|
bone marrow biopsy
cytogenetic analysis
molecular testing
|
|
gptkbp:hasFusionGene
|
gptkb:PML-RARA
|
|
gptkbp:hasGeneticAlteration
|
t(15;17)(q22;q12)
|
|
gptkbp:hasImmunophenotype
|
gptkb:HLA-DR_negative
CD13 positive
CD33 positive
CD34 negative
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
M3 AML
|
|
gptkbp:incidence
|
5-10% of AML cases
|
|
gptkbp:morphologicalType
|
promyelocytic leukemia
|
|
gptkbp:prognosis
|
generally favorable with treatment
|
|
gptkbp:subspecies
|
gptkb:acute_myeloid_leukemia
|
|
gptkbp:treatment
|
gptkb:all-trans_retinoic_acid
gptkb:arsenic_trioxide
|
|
gptkbp:bfsParent
|
gptkb:acute_promyelocytic_leukemia
|
|
gptkbp:bfsLayer
|
6
|